-
- Jonathan S. Jahr
- David Geffen School of Medicine at University of California Los Angeles, Ronald Reagan UCLA Medical Center, Los Angeles, California
-
- Nicole R Guinn
- Department of Anesthesiology, Center for Blood Conservation Duke University Medical Center, Durham, North Carolina
-
- David R. Lowery
- US Military, San Antonio, Texas
-
- Linda Shore-Lesserson
- Cardiovascular Anesthesiology, Northshore University Hospital, Manhasset, New York
-
- Aryeh Shander
- Department of Anesthesiology, Critical Care and Hyperbaric Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey
説明
<jats:p>Despite the exhaustive search for an acceptable substitute to erythrocyte transfusion, neither chemical-based products such as perfluorocarbons nor hemoglobin-based oxygen carriers have succeeded in providing a reasonable alternative to allogeneic blood transfusion. However, there remain scenarios in which blood transfusion is not an option, due to patient’s religious beliefs, inability to find adequately cross-matched erythrocytes, or in remote locations. In these situations, artificial oxygen carriers may provide a mortality benefit for patients with severe, life-threatening anemia. This article provides an up-to-date review of the history and development, clinical trials, new technology, and current standing of artificial oxygen carriers as an alternative to transfusion when blood is not an option.</jats:p>
収録刊行物
-
- Anesthesia & Analgesia
-
Anesthesia & Analgesia 132 (1), 119-129, 2019-03-27
Ovid Technologies (Wolters Kluwer Health)
